Penn Medicine Abramson Cancer Center
New Therapies and Current Patient Management of Lymphomas
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
ASH Updates on R/R cHL: How to Consider Pembro-GVH? What Is the Role of Radiation-Based Approaches? What Is the Feasibility of Targeting Multiple Pathways for Patients With Relapses?
FEATURING
Jakub Svoboda
- 86 views
- March 5, 2021
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
UPenn Expert Discussion on Lymphoma: Efficacy of Acalabrutinib for Severe COVID-19, Time-Limited Venetoclax / Obinutuzumab, Brentuximab Mono in HL
FEATURING
Stephen Schuster,
James Gerson,
Jakub Svoboda,
Elise Chong,
Sunita D. Nasta,
Douglas Beach,
Gamil Hanna
- 94 views
- March 3, 2021
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
ASH Updates on Large Cell & Aggressive Lymphomas: Antibody Loncastuximab Tesirine in R/R DLBCL, Glofitamab Step-Up Dosing in Hard-to-Treat R/R NHL, Subcutaneous Epcoritamab in R/R NHL, M-CHOP for DLBCL
FEATURING
Sunita D. Nasta
- 159 views
- March 2, 2021
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
ASH Updates on Lymphomas: 1L (Axi-Cel) in High-Risk DLBCL, Safety, Dosing and Feasibility of MB-CART2019 in R/R B-NHL, BTKi/mTOR/IMID Combo for R/R Richter's Transformation and De-Novo DLBCL, CNS Lymphoma Prevention, Primary CNS Lymphoma
FEATURING
Sunita D. Nasta
- 55 views
- March 2, 2021
